Cicletanine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cicletanine
Accession Number
DB12766
Type
Small Molecule
Groups
Investigational
Description

Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
CHG7QC509W
CAS number
89943-82-8
Weight
Average: 261.71
Monoisotopic: 261.0556563
Chemical Formula
C14H12ClNO2
InChI Key
CVKNDPRBJVBDSS-UHFFFAOYSA-N
InChI
InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3
IUPAC Name
3-(4-chlorophenyl)-6-methyl-1H,3H-furo[3,4-c]pyridin-7-ol
SMILES
CC1=C(O)C2=C(C=N1)C(OC2)C1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cicletanine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Cicletanine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cicletanine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Cicletanine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Cicletanine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cicletanine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Cicletanine.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Cicletanine.Approved, Withdrawn
AmbrisentanCicletanine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineCicletanine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Cicletanine.Approved
AtenololAtenolol may increase the hypotensive activities of Cicletanine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Cicletanine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cicletanine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cicletanine.Withdrawn
BepridilBepridil may increase the hypotensive activities of Cicletanine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Cicletanine.Approved
BethanidineBethanidine may increase the hypotensive activities of Cicletanine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Cicletanine.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Cicletanine.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Cicletanine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Cicletanine.Approved
BosentanBosentan may increase the hypotensive activities of Cicletanine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Cicletanine.Investigational
BretyliumBretylium may increase the hypotensive activities of Cicletanine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cicletanine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Cicletanine.Experimental
BupranololBupranolol may increase the hypotensive activities of Cicletanine.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cicletanine.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Cicletanine.Experimental
CafedrineCicletanine may increase the hypotensive activities of Cafedrine.Investigational
Candesartan cilexetilCandesartan may increase the hypotensive activities of Cicletanine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cicletanine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Cicletanine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cicletanine.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Cicletanine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Cicletanine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Cicletanine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Cicletanine.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Cicletanine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cicletanine.Approved
CilazaprilCilazapril may increase the hypotensive activities of Cicletanine.Approved
ClonidineClonidine may increase the hypotensive activities of Cicletanine.Approved
CloranololCicletanine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cicletanine.Approved, Illicit
CryptenamineCryptenamine may increase the hypotensive activities of Cicletanine.Approved
CyclopenthiazideCicletanine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Cicletanine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Cicletanine.Approved
DelaprilCicletanine may increase the hypotensive activities of Delapril.Experimental
DeserpidineCicletanine may increase the hypotensive activities of Deserpidine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cicletanine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cicletanine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cicletanine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Cicletanine.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Cicletanine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Cicletanine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cicletanine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cicletanine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cicletanine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Cicletanine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cicletanine.Approved, Illicit
DorzolamideDorzolamide may increase the hypotensive activities of Cicletanine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Cicletanine.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cicletanine.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Cicletanine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Cicletanine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Cicletanine.Approved
EndralazineEndralazine may increase the hypotensive activities of Cicletanine.Experimental
EpanololCicletanine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Cicletanine.Approved
EprosartanEprosartan may increase the hypotensive activities of Cicletanine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cicletanine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cicletanine.Illicit, Vet Approved
FelodipineFelodipine may increase the hypotensive activities of Cicletanine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Cicletanine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cicletanine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidFerulic acid may increase the hypotensive activities of Cicletanine.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Cicletanine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Cicletanine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Cicletanine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Cicletanine.Approved
GuanazodineCicletanine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Cicletanine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Cicletanine.Approved, Investigational
GuanoclorCicletanine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCicletanine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCicletanine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Cicletanine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cicletanine.Approved, Illicit
HexamethoniumHexamethonium may increase the hypotensive activities of Cicletanine.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Cicletanine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Cicletanine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Cicletanine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cicletanine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cicletanine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cicletanine.Approved, Illicit
IloprostIloprost may increase the hypotensive activities of Cicletanine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Cicletanine.Investigational
IndapamideIndapamide may increase the hypotensive activities of Cicletanine.Approved
IndenololIndenolol may increase the hypotensive activities of Cicletanine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Cicletanine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Cicletanine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cicletanine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Cicletanine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cicletanine.Approved
IsradipineIsradipine may increase the hypotensive activities of Cicletanine.Approved
KetanserinKetanserin may increase the hypotensive activities of Cicletanine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cicletanine.Approved
LabetalolLabetalol may increase the hypotensive activities of Cicletanine.Approved
LacidipineLacidipine may increase the hypotensive activities of Cicletanine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Cicletanine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Cicletanine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cicletanine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cicletanine.Approved
LinsidomineCicletanine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Cicletanine.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cicletanine.Illicit
LofexidineLofexidine may increase the hypotensive activities of Cicletanine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Cicletanine.Approved
MacitentanCicletanine may increase the hypotensive activities of Macitentan.Approved
ManidipineManidipine may increase the hypotensive activities of Cicletanine.Approved
MebanazineMebanazine may increase the hypotensive activities of Cicletanine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Cicletanine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Cicletanine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cicletanine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cicletanine.Approved, Illicit
MethoserpidineCicletanine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Cicletanine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cicletanine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cicletanine.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Cicletanine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Cicletanine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Cicletanine.Approved, Investigational
MetyrosineCicletanine may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Cicletanine.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Cicletanine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Cicletanine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Cicletanine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Cicletanine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Cicletanine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Cicletanine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cicletanine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Cicletanine.Approved
MuzolimineCicletanine may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the hypotensive activities of Cicletanine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Cicletanine.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cicletanine.Approved
NebivololNebivolol may increase the hypotensive activities of Cicletanine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Cicletanine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Cicletanine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Cicletanine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Cicletanine.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Cicletanine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Cicletanine.Approved
NimodipineNimodipine may increase the hypotensive activities of Cicletanine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Cicletanine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Cicletanine.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Cicletanine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cicletanine.Approved, Illicit
ObinutuzumabCicletanine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Cicletanine.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Cicletanine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Cicletanine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cicletanine.Approved, Illicit
OxprenololOxprenolol may increase the hypotensive activities of Cicletanine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cicletanine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cicletanine.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypotensive activities of Cicletanine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Cicletanine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Cicletanine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cicletanine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Cicletanine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cicletanine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Cicletanine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Cicletanine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Cicletanine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Cicletanine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Cicletanine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cicletanine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cicletanine.Approved
PinacidilPinacidil may increase the hypotensive activities of Cicletanine.Withdrawn
PindololPindolol may increase the hypotensive activities of Cicletanine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Cicletanine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Cicletanine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Cicletanine.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Cicletanine.Approved
PrazosinPrazosin may increase the hypotensive activities of Cicletanine.Approved
PropranololPropranolol may increase the hypotensive activities of Cicletanine.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Cicletanine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Cicletanine.Approved
RamiprilRamipril may increase the hypotensive activities of Cicletanine.Approved
RasagilineRasagiline may increase the hypotensive activities of Cicletanine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cicletanine.Approved
RemikirenRemikiren may increase the hypotensive activities of Cicletanine.Approved
RescinnamineCicletanine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Cicletanine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Cicletanine.Investigational
RiociguatCicletanine may increase the hypotensive activities of Riociguat.Approved
RituximabCicletanine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Cicletanine.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Cicletanine.Experimental
SelegilineSelegiline may increase the hypotensive activities of Cicletanine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Cicletanine.Approved
SildenafilSildenafil may increase the antihypertensive activities of Cicletanine.Approved, Investigational
SitaxentanCicletanine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphateCicletanine may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Cicletanine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Cicletanine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Cicletanine.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Cicletanine.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Cicletanine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Cicletanine.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Cicletanine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Cicletanine.Investigational
TheodrenalineCicletanine may increase the hypotensive activities of Theodrenaline.Investigational
TiboloneTibolone may increase the hypotensive activities of Cicletanine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Cicletanine.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Cicletanine.Experimental
TimololTimolol may increase the hypotensive activities of Cicletanine.Approved
TolazolineTolazoline may increase the hypotensive activities of Cicletanine.Approved, Vet Approved
TolonidineCicletanine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Cicletanine.Approved
TorasemideTorasemide may increase the hypotensive activities of Cicletanine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cicletanine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Cicletanine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cicletanine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Cicletanine.Approved
TravoprostTravoprost may increase the hypotensive activities of Cicletanine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cicletanine.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Cicletanine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Cicletanine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Cicletanine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Cicletanine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Cicletanine.Approved
UrapidilUrapidil may increase the hypotensive activities of Cicletanine.Investigational
ValsartanValsartan may increase the hypotensive activities of Cicletanine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cicletanine.Approved
VincamineCicletanine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Cicletanine.Investigational
XipamideCicletanine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Cicletanine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Cicletanine.Approved, Vet Approved
ZofenoprilCicletanine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
49583
ChEBI
135078
ChEMBL
CHEMBL191886
ATC Codes
C03BX03 — Cicletanine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2Not Yet RecruitingTreatmentArterial Hypertension / Diabetes / Hypokalaemia / Hyponatremias1
2TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.727 mg/mLALOGPS
logP2.8ALOGPS
logP2.6ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)8.57ChemAxon
pKa (Strongest Basic)5.51ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area42.35 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity69.68 m3·mol-1ChemAxon
Polarizability26.49 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Methylpyridines / Hydroxypyridines / Aryl chlorides / Heteroaromatic compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides
show 1 more
Substituents
Chlorobenzene / Methylpyridine / Hydroxypyridine / Aryl chloride / Aryl halide / Pyridine / Heteroaromatic compound / Dialkyl ether / Ether / Organoheterocyclic compound
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 18:05 / Updated on September 01, 2017 12:24